176 related articles for article (PubMed ID: 37062068)
1. Integrated analysis based on vesicle trafficking-related genes identifying CNIH4 as a novel therapeutic target for glioma.
Fang Z; Kong F; Zeng J; Zhang Z; Wang Y; Wang Y; Duan J; Chen L; Wang J; Liu F
Cancer Med; 2023 Jun; 12(11):12943-12959. PubMed ID: 37062068
[TBL] [Abstract][Full Text] [Related]
2. CNIH4: a novel biomarker connected with poor prognosis and cell proliferation in patients with lower-grade glioma.
Xiao F; Sun G; Zhu H; Guo Y; Xu F; Hu G; Huang K; Guo H
Am J Cancer Res; 2023; 13(5):2135-2154. PubMed ID: 37293170
[TBL] [Abstract][Full Text] [Related]
3. Potential roles of Cornichon Family AMPA Receptor Auxiliary Protein 4 (CNIH4) in head and neck squamous cell carcinoma.
Liu H; Li Y
Cancer Biomark; 2022; 35(4):439-450. PubMed ID: 36404537
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer.
Wang J; Wang S; Wang J; Huang J; Lu H; Pan B; Pan H; Song Y; Deng Q; Jin X; Shi G
Cancer Med; 2023 Dec; 12(24):22381-22394. PubMed ID: 38087815
[TBL] [Abstract][Full Text] [Related]
5. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Fibroblast-Related Prognostic Model in Glioma Based on Bioinformatics Methods.
Zhang H; Huang Y; Yang E; Gao X; Zou P; Sun J; Tian Z; Bao M; Liao D; Ge J; Yang Q; Li X; Zhang Z; Luo P; Jiang X
Biomolecules; 2022 Oct; 12(11):. PubMed ID: 36358948
[TBL] [Abstract][Full Text] [Related]
8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
10. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
11. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma.
Zhang M; Wang X; Chen X; Zhang Q; Hong J
Front Genet; 2020; 11():363. PubMed ID: 32351547
[TBL] [Abstract][Full Text] [Related]
12. Identification of an endoplasmic reticulum stress-related signature associated with clinical prognosis and immune therapy in glioma.
Li L; Yang Z; Zheng Y; Chen Z; Yue X; Bian E; Zhao B
BMC Neurol; 2022 May; 22(1):192. PubMed ID: 35614390
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
[TBL] [Abstract][Full Text] [Related]
14. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
15. A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma.
Wu Z; Liu M; Fu J; Li J; Qin L; Wu L; Chen H; Yan X; Liu Q; Zheng J
Biomed Res Int; 2022; 2022():3742447. PubMed ID: 35757472
[TBL] [Abstract][Full Text] [Related]
16. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel pyroptosis-related gene signature correlated with the prognosis of diffuse glioma patients.
Zhang Y; Xi F; Yu Q; Lou W; Zeng Z; Su N; Gao J; Duan S; Deng Y; Guo S; Lai S; Tang X; Zhang J
Ann Transl Med; 2021 Dec; 9(24):1766. PubMed ID: 35071460
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
19. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
20.
Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]